妇科肿瘤协作组第五届卵巢癌共识会议:上皮性卵巢癌临床试验中纳入患者报告结局的建议
该共识由妇科肿瘤协作组第五届卵巢癌共识会议制定,强调上皮性卵巢癌临床试验中患者报告结局(PRO)与健康相关生活质量评估和报告存在不足。共识就PRO终点的设定、测量工具选择、分析与报告,以及ISOQOL与CONSORT-PRO指南的依从提出推荐。
要点
- PRO终点应基于PRO假设、具情境特异性,并反映患者人群与治疗目标。
- 铂敏感晚期复发患者中无进展生存应由PRO支持;铂耐药或难治患者中无进展生存单独作为主要终点不充分。
- 推荐使用至健康相关生活质量确定性恶化时间等新方法衡量姑息化疗获益。
核心结论
- 妇科肿瘤协作组一致认同PRO及PRO终点在上皮性卵巢癌临床试验中的重要性,并强调须努力保证PRO数据收集的完整性、避免数据缺失。
- 无进展生存应由PRO支持(适用于铂敏感晚期复发患者);铂耐药或难治患者中无进展生存单独作为主要终点不充分,PRO应作为主要或共同主要终点纳入。
- 推荐采用至健康相关生活质量确定性恶化时间等新方法衡量姑息化疗的获益,并认同所有未来妇科肿瘤协作组上皮性卵巢癌试验应遵循ISOQOL与CONSORT-PRO指南。
研究设计与样本
- 妇科肿瘤协作组第五届卵巢癌共识会议设立题为「如何在临床试验中纳入PRO」的全体会议,本文为该会议所提建议的总结。
主要发现
- PRO终点应基于PRO假设、具情境特异性,并反映患者人群与治疗目标(如一线治疗、维持治疗、早期或晚期复发)。
- PRO终点决定试验中所用PRO测量工具的选择以及结果分析与报告的方式。
- 共识认同在铂敏感晚期复发患者中无进展生存应由PRO支持。
- 共识认为在铂耐药或难治性上皮性卵巢癌患者中,无进展生存单独作为主要终点不充分,PRO应作为主要或共同主要终点纳入。
- 会议推荐采用至健康相关生活质量确定性恶化时间等新方法衡量姑息化疗的获益。
关键数值与推荐
- 妇科肿瘤协作组一致认同PRO及PRO终点在上皮性卵巢癌临床试验中的重要性。
- 无进展生存应由PRO支持(铂敏感晚期复发患者)。
- 铂耐药或难治患者中无进展生存单独作为主要终点不充分,PRO应作为主要或共同主要终点。
- 推荐采用至健康相关生活质量确定性恶化时间等新方法衡量姑息化疗获益。
- 认同ISOQOL与CONSORT-PRO关于方案中纳入与报告PRO终点的指南,未来妇科肿瘤协作组上皮性卵巢癌试验应遵循这些指南。
临床怎么用
- 作者建议在上皮性卵巢癌临床试验中依据PRO假设与治疗情境设定PRO终点,并据此选择测量工具、分析及报告结果。
- 作者建议在铂敏感晚期复发患者中以PRO支持无进展生存,在铂耐药或难治患者中将PRO作为主要或共同主要终点。
- 作者推荐采用至健康相关生活质量确定性恶化时间等新方法衡量姑息化疗获益,并遵循ISOQOL与CONSORT-PRO指南。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the support for including patient-reported outcomes (PROs) and health-related quality of life in clinical trials, there have been deficiencies in how these have been assessed and reported in epithelial ovarian cancer (EOC) clinical trials. To redress this, the 5th Ovarian Cancer Consensus Conference, included a plenary session entitled 'How to include PROs in clinical trials'. The perspective is a summary of the recommendations made by the Gynecologic Cancer InterGroup unanimously agreed on the importance of PROs and PRO end-points in EOC clinical trials. They recognised that effort must be made to ensure the integrity of collection of PRO data and to avoid missing data. PRO end-points should be based on the PRO hypotheses, be context specific and reflect the patient population and the objectives of treatment (e.g. first line, maintenance therapy, early or late relapse). The PRO end-points inform the choice of PRO measures used in the trial and how the results are analysed and reported. There was agreement that progression-free survival should be supported by PROs among patients with late relapse (platinum sensitive) and that progression-free survival alone was not sufficient as the primary end-point of clinical trials in patients with platinum resistant/refractory EOC and PROs should be included as either the primary/co-primary end-point in this subset of patients. Novel approaches to measure the benefit of palliative chemotherapy such as time until definitive deterioration of Health-Related Quality of Life were recommended. There was consensus to endorse the ISOQOL and CONSORT-PRO guidelines on the inclusion and reporting of PRO endpoints in protocols and that all future EOC Gynecologic Cancer InterGroup trials should adhere to these.
引用
- Joly F, Hilpert F, Okamoto A, et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer. Eur J Cancer. 2017. PMID: 28448857. doi:10.1016/j.ejca.2017.03.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。